The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 13, Issue 2, 2013, Pages 175-183

  Subramani, Parasuraman Aiya ^a   Reddy, Madhava C ^a   Narala, Venkata R ^a  

^a YOGI VEMANA UNIVERSITY   (India)

Author keywords

Adipogenesis; Endogenous ligands; Inflammation; Macrophage; PPAR ; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) PROPOXY] PHENOXY] ACETIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; FARNESYL DIPHOSPHATE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOGENESIS; ARTICLE; BINDING AFFINITY; BONE DENSITY; CELL DIFFERENTIATION; DRUG RECEPTOR BINDING; FRACTURE; GENE EXPRESSION; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIDE EFFECT; SIGNAL TRANSDUCTION;

ADIPOCYTES; ANIMALS; DISEASE; DRUG DISCOVERY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNE SYSTEM; LIGANDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN CONFORMATION;

EID: 84888091980     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/18715303113139990003     Document Type: Article

References (113)

1. Bensinger, S.J. and Tontonoz, P. (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature, 454, 470-477.
2. Braissant, O. and Wahli, W. (1998) Differential expression of peroxisome proliferator-activated receptor-α -β and -γ during rat embryonic development. Endocrinology, 139, 2748-2754.
3. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; Palmer, C.N.; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M.; Staels, B. and Wahli, W. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 58, 726-741.
4. Uppenberg, J.; Svensson, C.; Jaki, M.; Bertilsson, G.; Jendeberg, L. and Berkenstam, A. (1998) Crystal structure of the ligand binding domain of the human nuclear receptor PPAR-γ J. Biol. Chem., 273, 31108-31112.
5. Schupp, M. and Lazar, M.A. (2010) Endogenous ligands for nuclear receptors: digging deeper. J. Biol. Chem., 285, 40409-40415.
6. Glass, C.K. and Rosenfeld, M.G. (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev., 14, 121-141.
7. Temple, K.A.; Cohen, R.N.; Wondisford, S.R.; Yu, C.; Deplewski, D. and Wondisford, F.E. (2005) An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor γ binding and activation on some PPAR response elements. J. Biol. Chem., 280, 3529-3540.
8. Zhu, Y.; Qi, C.; Korenberg, J.R.; Chen, X.N.; Noya, D.; Rao, M.S. and Reddy, J.K. (1995) Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. Proc. Natl. Acad. Sci. USA, 92, 7921-7925.
9. Fajas, L.; Fruchart, J.C. and Auwerx, J. (1998) PPARγ 3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett., 438, 55-60.
10. Green, S. (1992) Peroxisome proliferators: a model for receptor mediated carcinogenesis. Cancer Surv., 14, 221-232.
11. Motojima, K. (1993) Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions. Cell Struct. Funct., 18, 267-277.
12. Bishop-Bailey, D. and Wray, J. (2003) Peroxisome proliferatoractivated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat., 71, 1-22.
13. Voet, D. and Voet, J.G., Biochemistry. 4th ed. ed2011, USA: John Wiley and sons. 1772.
14. Lehmann, J.M.; Moore, L.B.; Smith-Oliver, T.A.; Wilkison, W.O.; Willson, T.M. and Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J. Biol. Chem., 270, 12953-12956.
15. Spiegelman, B.M. (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes, 47, 507-514.
16. Ohshima, K.; Mogi, M. and Horiuchi, M. (2012) Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation. Int. J. Vasc. Med., 2012, 508416.
17. Martin, H. (2010) Role of PPAR-γ in inflammation. Prospects for therapeutic intervention by food components. Mutat. Res., 690, 57-63.
18. Moraes, L.A.; Piqueras, L. and Bishop-Bailey, D. (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther., 110, 371-385.
19. Youssef, J. and Badr, M. (2004) Role of Peroxisome Proliferator- Activated Receptors in Inflammation Control. J. Biomed. Biotechnol., 2004, 156-166.
20. Duan, S.Z.; Usher, M.G. and Mortensen, R.M. (2008) Peroxisome proliferator-activated receptor-γ-mediated effects in the vasculature. Circ. Res., 102, 283-294.
21. Vidovic, D.; Busby, S.A.; Griffin, P.R. and Schurer, S.C. (2011) A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists. Chem. Med. Chem., 6, 94-103.
22. Berger, J.; Leibowitz, M.D.; Doebber, T.W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C.A.; Hayes, N.S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M.S.; Berger, G.D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S.P.; Tolman, R.L.; Smith, R.G. and Moller, D.E. (1999) Novel peroxisome proliferator-activated receptor (PPAR) γ; and PPARδ ligands produce distinct biological effects. J. Biol. Chem., 274, 6718-6725.
23. Yokoi, H.; Mizukami, H.; Nagatsu, A.; Tanabe, H. and Inoue, M. (2010) Hydroxy monounsaturated fatty acids as agonists for peroxisome proliferator-activated receptors. Biol. Pharm. Bull., 33, 854-861.
24. Krey, G.; Braissant, O.; L'Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M.G. and Wahli, W. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol., 11, 779-791.
25. Willson, T.M. and Wahli, W. (1997) Peroxisome proliferatoractivated receptor agonists. Curr. Opin. Chem. Biol., 1, 235-241.
26. Abdelrahman, M.; Sivarajah, A. and Thiemermann, C. (2005) Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res., 65, 772-781.
27. Chang, F.; Jaber, L.A.; Berlie, H.D. and O'Connell, M.B. (2007) Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother., 41, 973-983.
28. Penumetcha, M. and Santanam, N. (2012) Nutraceuticals as Ligands of PPARγ. PPAR. Res., 2012, 858352.
29. Giguere, V. (1999) Orphan nuclear receptors: from gene to function. Endocr. Rev., 20, 689-725.
30. Loiodice, F. and Pochetti, G. (2011) Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods. Curr. Top. Med. Chem., 11, 819-839.
31. Oyama, T.; Toyota, K.; Waku, T.; Hirakawa, Y.; Nagasawa, N.; Kasuga, J.I.; Hashimoto, Y.; Miyachi, H. and Morikawa, K. (2009) Adaptability and selectivity of human peroxisome proliferatoractivated receptor (PPAR) pan agonists revealed from crystal structures. Acta Crystallogr. D. Biol. Crystallogr., 65, 786-795.
32. Xu, H.E.; Lambert, M.H.; Montana, V.G.; Plunket, K.D.; Moore, L.B.; Collins, J.L.; Oplinger, J.A.; Kliewer, S.A.; Gampe, R.T., Jr.; McKee, D.D.; Moore, J.T. and Willson, T.M. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 98, 13919-13924.
33. Itoh, T.; Fairall, L.; Amin, K.; Inaba, Y.; Szanto, A.; Balint, B.L.; Nagy, L.; Yamamoto, K. and Schwabe, J.W. (2008) Structural basis for the activation of PPARγ by oxidized fatty acids. Nat. Struct. Mol. Biol., 15, 924-931.
34. Li, Y.; Zhang, J.; Schopfer, F.J.; Martynowski, D.; Garcia-Barrio, M.T.; Kovach, A.; Suino-Powell, K.; Baker, P.R.; Freeman, B.A.; Chen, Y.E. and Xu, H.E. (2008) Molecular recognition of nitrated fatty acids by PPAR γ. Nat. Struct. Mol. Biol., 15, 865-867.
35. Malapaka, R.R.; Khoo, S.; Zhang, J.; Choi, J.H.; Zhou, X.E.; Xu, Y.; Gong, Y.; Li, J.; Yong, E.L.; Chalmers, M.J.; Chang, L.; Resau, J.H.; Griffin, P.R.; Chen, Y.E. and Xu, H.E. (2012) Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J. Biol. Chem., 287, 183-195.
36. Jiang, C.; Ting, A.T. and Seed, B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86.
37. Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T.P. and Rastinejad, F. (2008) Structure of the intact PPAR-γ-RXR nuclear receptor complex on DNA. Nature, 456, 350-356.
38. Chen, S.; Johnson, B.A.; Li, Y.; Aster, S.; McKeever, B.; Mosley, R.; Moller, D.E. and Zhou, G. (2000) Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor γ (PPARγ) function. J. Biol. Chem., 275, 3733-3736.
39. Bai, L.; Jia, Y.; Viswakarma, N.; Huang, J.; Vluggens, A.; Wolins, N.E.; Jafari, N.; Rao, M.S.; Borensztajn, J.; Yang, G. and Reddy, J.K. (2011) Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse. Hepatology, 53, 1164-1174.
40. Viswakarma, N.; Jia, Y.; Bai, L.; Vluggens, A.; Borensztajn, J.; Xu, J. and Reddy, J.K. (2010) Coactivators in PPAR-Regulated Gene Expression. PPAR. Res., 2010, 250126.
41. Rosen, E.D.; Sarraf, P.; Troy, A.E.; Bradwin, G.; Moore, K.; Milstone, D.S.; Spiegelman, B.M. and Mortensen, R.M. (1999) PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell, 4, 611-617.
42. Farmer, S.R. (2005) Regulation of PPARγ activity during adipogenesis. Int. J. Obes. (Lond), 29 Suppl 1, S13-16.
43. Spiegelman, B.M. and Flier, J.S. (1996) Adipogenesis and obesity: rounding out the big picture. Cell, 87, 377-389.
44. Tontonoz, P.; Hu, E. and Spiegelman, B.M. (1994) Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell, 79, 1147-1156.
45. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A. and Chen, H. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest., 112, 1821-1830.
46. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L. and Ferrante, A.W., Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 1796-1808.
47. Lago, R.M.; Singh, P.P. and Nesto, R.W. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 370, 1129-1136.
48. Singh, N. (2004) Rosiglitazone and heart failure: long-term vigilance. J. Cardiovasc. Pharmacol. Ther., 9, 21-25.
49. Kung, J. and Henry, R.R. (2012) Thiazolidinedione safety. Expert. Opin. Drug Saf., 11, 565-579.
50. Panicker, G.K.; Karnad, D.R.; Salvi, V. and Kothari, S. (2012) Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J. Assoc. Physicians India, 60, 56-61.
51. Pothoulakis, C. (2009) Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol. Ther., 30, 826-833.
52. Lee, S.K.; Kim, H.J.; Chi, S.G.; Jang, J.Y.; Nam, K.D.; Kim, N.H.; Joo, K.R.; Dong, S.H.; Kim, B.H.; Chang, Y.W.; Lee, J.I. and Chang, R. (2005) [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-γ in HT-29 cells]. Korean J. Gastroenterol., 45, 328-334.
53. Breidert, T.; Callebert, J.; Heneka, M.T.; Landreth, G.; Launay, J.M. and Hirsch, E.C. (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem., 82, 615-624.
54. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J. and Glass, C.K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 391, 79-82.
55. Pascual, G.; Fong, A.L.; Ogawa, S.; Gamliel, A.; Li, A.C.; Perissi, V.; Rose, D.W.; Willson, T.M.; Rosenfeld, M.G. and Glass, C.K. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature, 437, 759-763.
56. Dushkin, M.I. (2012) Macrophage/foam cell is an attribute of inflammation: mechanisms of formation and functional role. Biochemistry (Mosc), 77, 327-338.
57. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Goforth, M.H.; Morel, C.R.; Subramanian, V.; Mukundan, L.; Red Eagle, A.; Vats, D.; Brombacher, F.; Ferrante, A.W. and Chawla, A. (2007) Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature, 447, 1116-1120.
58. Are, A.; Aronsson, L.; Wang, S.; Greicius, G.; Lee, Y.K.; Gustafsson, J.A.; Pettersson, S. and Arulampalam, V. (2008) Enterococcus faecalis from newborn babies regulate endogenous PPARγ activity and IL-10 levels in colonic epithelial cells. Proc. Natl. Acad. Sci. USA, 105, 1943-1948.
59. Kiss-Toth, E. and Roszer, T. (2008) PPARγ in Kidney Physiology and Pathophysiology. PPAR. Res., 2008, 183108.
60. 12,14-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest., 106, 189-197.
61. Yue Tl, T.L.; Chen, J.; Bao, W.; Narayanan, P.K.; Bril, A.; Jiang, W.; Lysko, P.G.; Gu, J.L.; Boyce, R.; Zimmerman, D.M.; Hart, T.K.; Buckingham, R.E. and Ohlstein, E.H. (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation, 104, 2588-2594.
62. Wayman, N.S.; Hattori, Y.; McDonald, M.C.; Mota-Filipe, H.; Cuzzocrea, S.; Pisano, B.; Chatterjee, P.K. and Thiemermann, C. (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-γ) reduce myocardial infarct size. FASEB J., 16, 1027-1040.
63. Syversen, U.; Stunes, A.K.; Gustafsson, B.I.; Obrant, K.J.; Nordsletten, L.; Berge, R.; Thommesen, L. and Reseland, J.E. (2009) Different skeletal effects of the peroxisome proliferator activated receptor (PPAR) γ agonist fenofibrate and the PPARγ agonist pioglitazone. BMC Endocr. Disord., 9, 10.
64. Reka, A.K.; Kurapati, H.; Narala, V.R.; Bommer, G.; Chen, J.; Standiford, T.J. and Keshamouni, V.G. (2010) Peroxisome proliferatoractivated receptor-γ activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol. Cancer Ther., 9, 3221-3232.
65. Jansson, E.A.; Are, A.; Greicius, G.; Kuo, I.C.; Kelly, D.; Arulampalam, V. and Pettersson, S. (2005) The Wnt/β-catenin signaling pathway targets PPARγ activity in colon cancer cells. Proc. Natl. Acad. Sci. USA, 102, 1460-1465.
66. Reddy, R.C.; Narala, V.R.; Keshamouni, V.G.; Milam, J.E.; Newstead, M.W. and Standiford, T.J. (2008) Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-γ. Blood, 112, 4250- 4258.
67. Zeng, X.L.; Liu, X.J.; Bao, H.R.; Zhang, Y.; Tan, E.L. and Liao, J.M. (2011) Effects of rosiglitazone on peroxisome proliferator activated receptor-γ pathway in patients with chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi, 34, 743-748.
68. Lefebvre, M.; Paulweber, B.; Fajas, L.; Woods, J.; McCrary, C.; Colombel, J.F.; Najib, J.; Fruchart, J.C.; Datz, C.; Vidal, H.; Desreumaux, P. and Auwerx, J. (1999) Peroxisome proliferatoractivated receptor γ is induced during differentiation of colon epithelium cells. J. Endocrinol., 162, 331-340.
69. Cipolletta, D.; Feuerer, M.; Li, A.; Kamei, N.; Lee, J.; Shoelson, S.E.; Benoist, C. and Mathis, D. (2012) PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature, 486, 549-553.
70. Natarajan, C.; Muthian, G.; Barak, Y.; Evans, R.M. and Bright, J.J. (2003) Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol., 171, 5743-5750.
71. Schinner, S.; Kratzner, R.; Baun, D.; Dickel, C.; Blume, R. and Oetjen, E. (2009) Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor γ and thiazolidinedione oral antidiabetic drugs. Br. J. Pharmacol., 157, 736-745.
72. Duan, S.Z.; Usher, M.G. and Mortensen, R.M. (2009) PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens., 18, 128-133.
73. Lin, Q.; Jia, L. and Sun, Y. (2012) A pilot study of circulating PPAR-γ receptor protein in elderly patients with atrial fibrillation. Arch. Med. Sci., 8, 471-476.
74. Wan, Y.; Saghatelian, A.; Chong, L.W.; Zhang, C.L.; Cravatt, B.F. and Evans, R.M. (2007) Maternal PPAR γ protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev., 21, 1895-1908.
75. Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645-650.
76. Kliewer, S.A.; Lenhard, J.M.; Willson, T.M.; Patel, I.; Morris, D.C. and Lehmann, J.M. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell, 83, 813-819.
77. Goto, T.; Nagai, H.; Egawa, K.; Kim, Y.I.; Kato, S.; Taimatsu, A.; Sakamoto, T.; Ebisu, S.; Hohsaka, T.; Miyagawa, H.; Murakami, S.; Takahashi, N. and Kawada, T. (2011) Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist. Biochem. J., 438, 111-119.
78. Kobayashi, T. and Fujimori, K. (2012) Very long-chain-fatty acids enhance adipogenesis through coregulation of Elovl3 and PPARγ in 3T3-L1 cells. Am. J. Physiol. Endocrinol. Metab., 302, E1461-E1471.
79. Schopfer, F.J.; Lin, Y.; Baker, P.R.; Cui, T.; Garcia-Barrio, M.; Zhang, J.; Chen, K.; Chen, Y.E. and Freeman, B.A. (2005) Nitrolinoleic acid: an endogenous peroxisome proliferatoractivated receptor γ ligand. Proc. Natl. Acad. Sci. USA, 102, 2340-2345.
80. Bjorndal, B.; Grimstad, T.; Cacabelos, D.; Nylund, K.; Aasprong, O.G.; Omdal, R.; Portero-Otin, M.; Pamplona, R.; Lied, G.A.; Hausken, T. and Berge, R.K. (2013) Tetradecylthioacetic Acid Attenuates Inflammation and Has Antioxidative Potential During Experimental Colitis in Rats. Dig. Dis. Sci., 58, 97-106.
81. Reddy, A.T.; Lakshmi, S.P. and Reddy, R.C. (2012) The Nitrated Fatty Acid 10-Nitro-oleate Diminishes Severity of LPS-Induced Acute Lung Injury in Mice. PPAR. Res., 2012, 617063.
82. Ma, Y.; Wang, S.Q.; Xu, W.R.; Wang, R.L. and Chou, K.C. (2012) Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One, 7, e38546.
83. Lewis, S.N.; Bassaganya-Riera, J. and Bevan, D.R. (2010) Virtual Screening as a Technique for PPAR Modulator Discovery. PPAR. Res., 2010, 861238.
84. Cho, M.C.; Lee, H.S.; Kim, J.H.; Choe, Y.K.; Hong, J.T.; Paik, S.G. and Yoon, D.Y. (2003) A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-γ. J. Biochem. Mol. Biol., 36, 207-213.
85. Ye, Y.; Nishi, S.P.; Manickavasagam, S.; Lin, Y.; Huang, M.H.; Perez-Polo, J.R.; Uretsky, B.F. and Birnbaum, Y. (2007) Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid Mediat., 84, 43-53.
86. Kliewer, S.A.; Sundseth, S.S.; Jones, S.A.; Brown, P.J.; Wisely, G.B.; Koble, C.S.; Devchand, P.; Wahli, W.; Willson, T.M.; Lenhard, J.M. and Lehmann, J.M. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA, 94, 4318-4323.
87. Narala, V.R.; Smith, M.R.; Adapala, R.K.; Ranga, R.; Panati, K.; Moore, B.B.; Leff, T.; Reddy, V.D.; Kondapi, A.K. and Reddy, R.C. (2009) Curcumin is not a ligand for peroxisome proliferatoractivated receptor-γ. Gene Ther. Mol. Biol., 13, 20-25.
88. Barroso, I.; Gurnell, M.; Crowley, V.E.; Agostini, M.; Schwabe, J.W.; Soos, M.A.; Maslen, G.L.; Williams, T.D.; Lewis, H.; Schafer, A.J.; Chatterjee, V.K. and O'Rahilly, S. (1999) Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 402, 880-883.
89. Barak, Y.; Nelson, M.C.; Ong, E.S.; Jones, Y.Z.; Ruiz-Lozano, P.; Chien, K.R.; Koder, A. and Evans, R.M. (1999) PPAR γ is required for placental, cardiac, and adipose tissue development. Mol. Cell., 4, 585-595.
90. Oberfield, J.L.; Collins, J.L.; Holmes, C.P.; Goreham, D.M.; Cooper, J.P.; Cobb, J.E.; Lenhard, J.M.; Hull-Ryde, E.A.; Mohr, C.P.; Blanchard, S.G.; Parks, D.J.; Moore, L.B.; Lehmann, J.M.; Plunket, K.; Miller, A.B.; Milburn, M.V.; Kliewer, S.A. and Willson, T.M. (1999) A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA, 96, 6102-6106.
91. Rocchi, S.; Picard, F.; Vamecq, J.; Gelman, L.; Potier, N.; Zeyer, D.; Dubuquoy, L.; Bac, P.; Champy, M.F.; Plunket, K.D.; Leesnitzer, L.M.; Blanchard, S.G.; Desreumaux, P.; Moras, D.; Renaud, J.P. and Auwerx, J. (2001) A unique PPARγligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell, 8, 737-747.
92. Kulkarni, A.A.; Woeller, C.F.; Thatcher, T.H.; Ramon, S.; Phipps, R.P. and Sime, P.J. (2012) Emerging PPARγ -Independent Role of PPARγ Ligands in Lung Diseases. PPAR. Res., 2012, 705352.
93. Ferguson, H.E.; Kulkarni, A.; Lehmann, G.M.; Garcia-Bates, T.M.; Thatcher, T.H.; Huxlin, K.R.; Phipps, R.P. and Sime, P.J. (2009) Electrophilic peroxisome proliferator-activated receptor-γ ligands have potent antifibrotic effects in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol., 41, 722-730.
94. Fu, M.; Sun, T.; Bookout, A.L.; Downes, M.; Yu, R.T.; Evans, R.M. and Mangelsdorf, D.J. (2005) A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. Mol. Endocrinol., 19, 2437-2450.
95. Singh, S. and Loke, Y.K. (2008) The safety of rosiglitazone in the treatment of type 2 diabetes. Expert. Opin. Drug Saf., 7, 579-585.
96. Krentz, A.J.; Bailey, C.J. and Melander, A. (2000) Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ, 321, 252-253.
97. Camp, H.S.; Li, O.; Wise, S.C.; Hong, Y.H.; Frankowski, C.L.; Shen, X.; Vanbogelen, R. and Leff, T. (2000) Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes, 49, 539-547.
98. Bermudez, V.; Finol, F.; Parra, N.; Parra, M.; Perez, A.; Penaranda, L.; Vilchez, D.; Rojas, J.; Arraiz, N. and Velasco, M. (2010) PPAR-γ agonists and their role in type 2 diabetes mellitus management. Am. J. Ther., 17, 274-283.
99. Kodera, Y.; Takeyama, K.; Murayama, A.; Suzawa, M.; Masuhiro, Y. and Kato, S. (2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. J. Biol. Chem., 275, 33201-33204.
100. Heinlein, C.A.; Ting, H.J.; Yeh, S. and Chang, C. (1999) Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ J. Biol. Chem., 274, 16147-16152.
101. Calkin, A.C. and Thomas, M.C. (2008) PPAR agonists and cardiovascular disease in diabetes. PPAR. Res., 2008, 245-410.
102. Tzameli, I.; Fang, H.; Ollero, M.; Shi, H.; Hamm, J.K.; Kievit, P.; Hollenberg, A.N. and Flier, J.S. (2004) Regulated production of a peroxisome proliferator-activated receptor-γ ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J. Biol. Chem., 279, 36093-36102.
103. Hamza, M.S.; Pott, S.; Vega, V.B.; Thomsen, J.S.; Kandhadayar, G.S.; Ng, P.W.; Chiu, K.P.; Pettersson, S.; Wei, C.L.; Ruan, Y. and Liu, E.T. (2009) De-novo identification of PPARγ/RXR binding sites and direct targets during adipogenesis. PLoS One, 4, e4907.
104. Bystrom, J.; Wray, J.A.; Sugden, M.C.; Holness, M.J.; Swales, K.E.; Warner, T.D.; Edin, M.L.; Zeldin, D.C.; Gilroy, D.W. and Bishop-Bailey, D. (2011) Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One, 6, e26591.
105. Thuillier, P.; Brash, A.R.; Kehrer, J.P.; Stimmel, J.B.; Leesnitzer, L.M.; Yang, P.; Newman, R.A. and Fischer, S.M. (2002) Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem. J., 366, 901-910.
106. Yang, Z.H.; Miyahara, H.; Iwasaki, Y.; Takeo, J. and Katayama, M. (2013) Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR γ in adipose tissue in type 2 diabetic KK- Ay mice. Nutr. Metab. (Lond), 10, 16.
107. Perez-Matute, P.; Perez-Echarri, N.; Martinez, J.A.; Marti, A. and Moreno-Aliaga, M.J. (2007) Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-α. Br. J. Nutr., 97, 389-398.
108. Kang, J.H.; Kim, C.S.; Han, I.S.; Kawada, T. and Yu, R. (2007) Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages. FEBS Lett., 581, 4389-4396.
109. Soares, F.L.; de Oliveira Matoso, R.; Teixeira, L.G.; Menezes, Z.; Pereira, S.S.; Alves, A.C.; Batista, N.V.; de Faria, A.M.; Cara, D.C.; Ferreira, A.V. and Alvarez-Leite, J.I. (2012) Gluten-free diet reduces adiposity, inflammation and insulin resistance associated with the induction of PPAR-γ and PPAR-γ expression. J. Nutr. Biochem., S0955-2863(12) 00224-00226
110. Kao, Y.H.; Chang, H.H.; Lee, M.J. and Chen, C.L. (2006) Tea, obesity, and diabetes. Mol. Nutr. Food Res., 50, 188-210.
111. Hirai, S.; Takahashi, N.; Goto, T.; Lin, S.; Uemura, T.; Yu, R. and Kawada, T. (2010) Functional food targeting the regulation of obesity-induced inflammatory responses and pathologies. Mediators Inflamm., 2010, 367-838.
112. Aggarwal, B.B. (2010) Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr., 30, 173-199.
113. Narala, V.R.; Adapala, R.K.; Suresh, M.V.; Brock, T.G.; Peters- Golden, M. and Reddy, R.C. (2010) Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferatoractivated receptor-γ agonist. J. Biol. Chem., 285, 22067-22074.